Skip to content
Peptigraph home

CagriSema

Amylin + GLP-1 combination. CagriSema is investigational and not approved for any use.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusInvestigational · filed with FDAProhibited by WADA (S0)Full legal history

Key facts

How we verify
Class
Amylin + GLP-1 combination
Also called
No common aliases
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
FDA status
Not approved
Investigational · filed with FDA
WADA
Prohibited (S0)
In and out of competition
Everything on CagriSema

CagriSema guides

DosageDoses used in published studies, with the source for each.For weight lossWhat research says about CagriSema for weight loss.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

CagriSema: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger10Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42009015

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Common questions

Is CagriSema FDA approved?

No. CagriSema is investigational (investigational · filed with fda) and not approved for any use.

Is CagriSema banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cagrisema" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
  5. 5Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026

Found an error? Report a correction.